Nuvectis Pharma (NASDAQ:NVCT) Shares Down 5.2% – Here’s What Happened

Nuvectis Pharma, Inc. (NASDAQ:NVCT)’s stock price fell 5.2% during trading on Wednesday . The stock traded as low as $24.27 and last traded at $24.5340. Approximately 43,397 shares traded hands during trading, a decline of 74% from the average session volume of 166,446 shares. The stock had previously closed at $25.89.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Weiss Ratings upgraded shares of Nuvectis Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Wall Street Zen upgraded shares of Nuvectis Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Roth Capital lifted their target price on Nuvectis Pharma from $20.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, July 6th. Cantor Fitzgerald initiated coverage on Nuvectis Pharma in a research note on Monday. They set an “overweight” rating on the stock. Finally, HC Wainwright upped their price target on Nuvectis Pharma from $13.00 to $39.00 and gave the company a “buy” rating in a report on Monday, June 22nd. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Nuvectis Pharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.00.

Nuvectis Pharma Price Performance

The stock has a market cap of $802.00 million, a price-to-earnings ratio of -18.80 and a beta of -0.26. The stock’s 50 day simple moving average is $20.07 and its two-hundred day simple moving average is $13.01.

Nuvectis Pharma (NASDAQ:NVCT) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). As a group, analysts predict that Nuvectis Pharma, Inc. will post -0.98 earnings per share for the current year.

Insider Transactions at Nuvectis Pharma

In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri purchased 50,000 shares of the business’s stock in a transaction on Tuesday, June 30th. The stock was purchased at an average price of $18.32 per share, for a total transaction of $916,000.00. Following the completion of the purchase, the insider directly owned 3,186,576 shares in the company, valued at approximately $58,378,072.32. This trade represents a 1.59% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Ron Bentsur acquired 12,500 shares of the firm’s stock in a transaction on Tuesday, June 30th. The shares were bought at an average cost of $20.00 per share, for a total transaction of $250,000.00. Following the completion of the acquisition, the chief executive officer directly owned 3,688,424 shares of the company’s stock, valued at approximately $73,768,480. This represents a 0.34% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 28.55% of the company’s stock.

Hedge Funds Weigh In On Nuvectis Pharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. Legal & General Group Plc acquired a new stake in Nuvectis Pharma in the 2nd quarter valued at $31,000. California State Teachers Retirement System raised its stake in Nuvectis Pharma by 376.8% during the second quarter. California State Teachers Retirement System now owns 3,991 shares of the company’s stock worth $73,000 after acquiring an additional 3,154 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Nuvectis Pharma by 3,398.9% during the second quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company’s stock valued at $47,000 after acquiring an additional 6,084 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Nuvectis Pharma during the second quarter valued at $53,000. Finally, Bank of America Corp DE boosted its stake in shares of Nuvectis Pharma by 417.2% in the 2nd quarter. Bank of America Corp DE now owns 8,565 shares of the company’s stock valued at $64,000 after purchasing an additional 6,909 shares in the last quarter. Institutional investors own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.